Authors: Ineke van Daele; Serge van Calenbergh

Source: Expert Opinion on Therapeutic Patents, Volume 15, Number 2, 1 February 2005 , pp. 131-140(10)

Publisher: Informa Healthcare

Abstract:

At present, clinical management of patients infected with Mycobacterium tuberculosis faces difficult problems, such as the worldwide emergence of multidrug resistant tuberculosis (MDR-TB), and the increase in AIDS-associated infections. Development of new drugs with greater or distinct antimycobacterial activity than those currently used is, therefore, urgently desired. Three main strategies toward this effort are pursued: discovery of new targets; structural modification of existing antibiotics; and identification of nat-ural resources for novel antibiotics.

Keywords: drug discovery; drug lead; Mycobacterium tuberculosis; tuberculosis (TB)

Document Type: Review article

DOI: http://dx.doi.org/10.1517/13543776.15.2.131

Publication date: 2005-02-01

More about this publication?

• Editorial Board
• Information for Authors
• Subscribe to this Title
• Terms & Conditions
• ingentaconnect is not responsible for the content or availability of external websites

Related content

• In this: publication
• By this: publisher
• In this Subject: Pharmacology
• By this author: Ineke van Daele ;  Serge van Calenbergh

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers